Full Year 2024 Financial Guidance: DAYBUE net product sales in the range of $370 to $420 million. NUPLAZID net product sales in the range of $560 to $590 million. GAAP R&D expense in the range of $305 to $325 million. GAAP SG&A expense in the range of $455 to $480 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACAD:
